Arthneeti

Aakaar Medical Technologies Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 28 May 2026 | Personal Products | Market Cap: ₹95 Cr

Targeting a CAGR of 30% going forward to maintain strong growth. Management targets a CAGR of 30% and above for revenue growth going forward.

From Aakaar Medical Technologies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹61.3

Market Cap

₹95 Cr

P/E Ratio

14.3

How does Aakaar Medical Technologies Ltd rank in Personal Products?

Compare Aakaar Medical Technologies Ltd against every Personal Products company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 2Margin: Rank 3
View Personal Products leaderboard →

📊 Revenue & Sales Performance

Rank 2
  • →Targeting a CAGR of 30% going forward to maintain strong growth.
  • →New brands like Letybo, Xomage, and VM Portfolio expected to significantly boost top line.
  • →Focus on growing top 10 brands, currently contributing 65-67% of revenue.
  • →Expansion plans include increasing presence in hair transplant and consumables markets.
  • →Xelix clinic platform to drive growth by integrating marketing and expanding doctor participation.
  • →Hair care category with proprietary products like DRS1512 has potential to reach several hundred crores in revenue.
  • →Expected growth driven by stabilized portfolio, launch of new products, and USFDA-approved filler.
  • →Operational efficiencies and expanded team expected to support scalable growth.
  • →Shift to distributor model aims to improve margins and credit control, supporting sales expansion.

See what Aakaar Medical Technologies Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

No
  • →Currently, there is no major CAPEX planned for clinic expansion as the Xelix clinic model is doctor-operated with no direct CAPEX from Aakaar; clinics are tied up under the Xelix platform without ownership by the company.
  • →Future plans may involve taking franchise fees from new doctors in the Xelix platform, indicating potential strategic investment in scaling this platform.
  • →Investment is underway in manufacturing and developing an exclusive hair transplant device, aiming for patenting and improving transplant success rates, which is an early-stage strategic capital commitment.
  • →Continued deployment of IPO proceeds towards strategic growth initiatives, operational strengthening, and long-term value creation, including working capital rationalization.
  • →Investments have been made upfront in building teams and inventory to support expansion and new product launches.

See what Aakaar Medical Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

No information
The transcript does not explicitly mention the current or expected order book or pending orders for Aakaar Medical Technologies Limited. However, the following related insights can be noted: - The company is working on strategic growth initiatives and operational strengthening post-IPO deployment. - New product launches like Letybo, Xomage, VM Portfolio are expected to boost the top line. - Focus on expanding the consumable portfolio to increase revenues. - Distributor model adoption is expected to improve margins and cash flow. - Significant investments made in expanding reach, including interior markets. - Working capital utilization is planned, with around 23 crores of IPO proceeds balanced for 2025-26 and 2026-27. - The second half of FY26 showed strong recovery, indicating growing demand. - No direct figures on order backlog or pending orders were disclosed in the transcript.

Key Metrics

0 of 5 growth signals positive in the Q4 FY26 call.

Revenue

Rank 2

Margin

Rank 3

Capex

No

Fundraise

No information

Order Book

No information

How does Aakaar Medical Technologies Ltd rank vs peers in Personal Products?

Pro feature
1Aakaar Medical Technologies Ltd
Rev 2Mar 3

See full Personal Products sector rankings

Continue your research

What AAKAAR's management said in earlier quarters

Others in Personal Products this season

  • HONASA (Q4 FY26)

    Increasing contribution from focus categories, which grew 35% year-on-year and now receive over 90% of investments. Key concall takeaways from Honasa Consumer…

  • Bajaj Consumer Care Ltd (Q4 FY26)

    Revenue growth momentum is strong, with a 21% increase for the full year FY26 and a 30% top-line growth noted in Q4. Key concall takeaways from Bajaj Consumer…

  • Gillette India Ltd (Q4 FY26)

    Female grooming is growing upwards of 20%, with continued investment to drive category expansion, especially through Venus. Key concall takeaways from…

  • Procter & Gamble Hygiene and Health Care Ltd (Q4 FY26)

    Healthcare sub-categories are growing at about 2-3%, with some recent volatility due to seasonal factors like monsoons. Key concall takeaways from PGHH's Q4…

Compare:vs GODREJCPvs DABURvs COLPAL

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aakaar Medical Technologies Ltd Q4 FY26 results?

Targeting a CAGR of 30% going forward to maintain strong growth. Management targets a CAGR of 30% and above for revenue growth going forward.

What is Aakaar Medical Technologies Ltd share price analysis?

Aakaar Medical Technologies Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 14.3 with a market cap of ₹95 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aakaar Medical Technologies Ltd planning capital expenditure?

Currently, there is no major CAPEX planned for clinic expansion as the Xelix clinic model is doctor-operated with no direct CAPEX from Aakaar; clinics are tied up under the Xelix platform without ownership by the company.

Keep Aakaar Medical Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.